Milestone Pharmaceuticals (MIST) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 28.7% versus a loss of 63.5%. Over five years, UNCY leads with a -86.8% price change compared with -87.3% for MIST. Unicycive Therapeutics is the larger company by market cap ($92.0 million vs $88.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | UNCY |
|---|---|---|
| Share price | $0.7073 | $3.36 |
| Market cap | $88.06M | $92.04M |
| 1-day change | -10.98% | -6.41% |
| YTD return | -64.99% | -41.77% |
| 1-year return | -63.54% | -28.66% |
| 5-year return | -87.27% | -86.77% |
| Forward P/E | — | 1.99 |
| EPS (TTM) | $-0.68 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.06M | $-26.55M |
| 52-week high | $3.06 | $8.74 |
| 52-week low | $0.704 | $3.35 |
| Distance from 52-week high | -76.89% | -61.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +728.50% | +745.24% |
| Average volume | 1.42M | 845.87K |
| Shares outstanding | 124.50M | 27.39M |
| Employees | 38 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed MIST by 34.9 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MIST vs UNCY FAQ
Which is bigger, Milestone Pharmaceuticals or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $92.04M compared with $88.06M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or UNCY?
UNCY returned -28.66% over the past 12 months, compared with -63.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.